Sehgal Virendra N, Pandhi Deepika, Khurana Ananta
Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Delhi, India.
Department of Dermatology and STD, University College of Medical Sciences and Associated Guru Teg Bahadur Hospital, Delhi, India.
Indian J Dermatol. 2014 Sep;59(5):425-41. doi: 10.4103/0019-5154.139859.
The advent of biologics in dermatologic treatment armentarium has added refreshing dimensions, for it is a major breakthrough. Several agents are now available for use. It is therefore imperative to succinctly comprehend their pharmacokinetics for their apt use. A concerted endeavor has been made to delve on this subject. The major groups of biologics have been covered and include: Drugs acting against TNF-α, Alefacept, Ustekinumab, Rituximab, IVIG and Omalizumab. The relevant pharmacokinetic characteristics have been detailed. Their respective label (approved) and off-label (unapproved) indications have been defined, highlighting their dosage protocol, availability and mode of administration. The evidence level of each indication has also been discussed to apprise the clinician of their current and prospective uses. Individual anti-TNF drugs are not identical in their actions and often one is superior to the other in a particular disease. Hence, the section on anti-TNF agents mentions the literature on each drug separately, and not as a group. The limitations for their use have also been clearly brought out.
生物制剂进入皮肤科治疗领域带来了全新的维度，因为这是一项重大突破。现在有几种药物可供使用。因此，为了合理使用它们，必须简要了解它们的药代动力学。人们已经齐心协力深入研究这个课题。生物制剂的主要类别已涵盖，包括：抗TNF-α药物、阿法赛特、乌司奴单抗、利妥昔单抗、静脉注射免疫球蛋白和奥马珠单抗。相关的药代动力学特征已详细说明。已明确它们各自的标签（批准）和非标签（未批准）适应症，突出了它们的给药方案、可用性和给药方式。还讨论了每种适应症的证据水平，以使临床医生了解它们当前和未来的用途。个别抗TNF药物的作用并不相同，在特定疾病中，一种药物往往优于另一种。因此，抗TNF药物部分分别提及了每种药物的文献，而不是作为一个整体。它们使用的局限性也已明确指出。
